|1.||Arnulf, Isabelle: 3 articles (06/2014 - 03/2012)|
|2.||Konofal, Eric: 3 articles (01/2014 - 01/2008)|
|3.||Lecendreux, Michel: 3 articles (01/2014 - 01/2008)|
|4.||Leu-Semenescu, Smaranda: 2 articles (06/2014 - 01/2013)|
|5.||Franco, Patricia: 2 articles (01/2013 - 03/2012)|
|6.||Halpern, Alfredo: 2 articles (04/2006 - 01/2005)|
|7.||Mancini, Marcio C: 2 articles (04/2006 - 01/2005)|
|8.||Radominski, R: 1 article (08/2014)|
|9.||Cunha, D R: 1 article (08/2014)|
|10.||dos Santos, C M C: 1 article (08/2014)|
02/01/1984 - "The increased level of liver and serum lipid induced by GTG-obesity was also found to be improved by mazindol. "
03/01/1977 - "A multi-centre general practice trial of mazindol in the treatment of obesity."
11/12/1976 - "[Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)]."
05/01/1976 - "[Results in the treatment of obesity by Mazindol (AN 448 Sandoz) in hospitalized subjects using the method of double-blind trial (author's transl)]."
06/01/2014 - "Mazindol is a sympathomimetic amine, widely used as an anorectic agent in the treatment of obesity. "
|2.||Weight Loss (Weight Reduction)
09/01/1978 - "In the mazindol-treated group the mean weight loss was 13.5 kg (22.3%) which was significantly greater (p less than 0.001) than in the placebo treated group where the mean weight loss was 4.2 kg (9.8%). "
05/01/2007 - "In the present study, the allelic frequency of the Trp64Arg ADRB3 gene polymorphism was determined in massively obese Japanese outpatients (BMI > 35 kg/m(2)), and we investigated whether allelic differences may determine the weight loss effect of mazindol. "
01/01/2008 - "With regard to the therapeutic implications, we suggest that wake-promoting agents with anorexigenic effect, such as mazindol, might be particularly indicated for the treatment of ADHD symptoms in obese patients, since they might address both ADHD symptoms and weight reduction. "
05/01/2007 - "Trp64Arg heterozygotes experienced significantly increased weight loss and reduced blood pressure following mazindol administration for 12 weeks. "
05/01/2007 - "Incidence of β3-adrenergic receptor polymorphism and prediction of successful weight reduction with mazindol therapy in severely obese Japanese subjects."
|3.||Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
12/01/1989 - "A simple-blind therapeutic trial of mazindol (2 mg/d) versus placebo in 14 boys with Duchenne muscular dystrophy, 5 to 13 years old, for 12 months was conducted in order to analyse the efficacy of this drug on the natural history of the disease. "
12/01/1989 - "[A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. "
01/23/1988 - "Mazindol in Duchenne muscular dystrophy."
12/01/1988 - "Mazindol has been reported to improve muscle function in Duchenne muscular dystrophy (DMD) by virtue of its growth hormone (GH) suppression. "
07/01/1986 - "A controlled, double-blind therapeutic trial with the drug mazindol, a growth hormone inhibitor, was performed in a pair of 7 1/2 year-old monozygotic twins, with Duchenne muscular dystrophy (DMD). "
|4.||Body Weight (Weight, Body)
12/01/1996 - "We attempted to study whether a further decrease in body weight would be achieved by the administration of mazindol, because it is difficult to obtain sufficient and continuous reduction of body weight after VLCD therapy. "
01/01/1992 - "A multicenter open study of mazindol in Japan revealed that loss of body weight and relative body weight in 14 wk were 4.6 kg and 9.2%, respectively, with suppression of appetite in the majority of obese patients. "
05/01/2007 - "Mazindol, a centrally acting monoamine re-uptake inhibitor, enhances satiety and supports body weight loss, but response to this drug among obese patients is very variable. "
11/01/1995 - "With mazindol, 53.3% of obese subjects kept the reduced body weight after VLCD, in contrast, 20.0% of them kept it without mazindol. "
11/01/1995 - "In long-term effects of mazindol, the average reduction of individual body weight was around 6.8 kg. The appetite of 59% of obese subjects was moderately suppressed. "
|5.||Cocaine-Related Disorders (Cocaine Addiction)
10/01/1995 - "Mazindol treatment for cocaine dependence."
01/01/1990 - "Mazindol treatment of cocaine abuse. "
02/04/1989 - "Treatment of cocaine abuse with mazindol."
02/01/2014 - "Mazindol has been explored as a possible agent in cocaine addiction pharmacotherapy. "
06/01/1992 - "Mazindol and cocaine addiction in schizophrenia."
|7.||Caffeine (No Doz)
|8.||Growth Hormone (Somatotropin)
|10.||Adrenergic Agents (Adrenergic Drugs)
|3.||Drug Therapy (Chemotherapy)